Rallybio Corp
RLYB
View Detailed Chart
0.589USD
-0.011-1.77%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
24.55MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.77%
5 Days
-2.03%
1 Month
+3.44%
6 Months
-19.26%
Year to Date
-38.69%
1 Year
-46.49%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Hold
Current Rating
1.000
Target Price
+66.89%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Growing
The company is in a growing phase, with the latest annual income totaling USD 636.00K.
Overvalued
The company’s latest PE is -0.64, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 33.40M shares, decreasing 13.51% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 4.19M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.43.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Ticker SymbolRLYB
CompanyRallybio Corp
CEODr. Stephen (Steve) Uden, M.D.
Websitehttps://rallybio.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
